SOHO 2021 | Chemoresistance and drug profiling in ALL
Beat C. Bornhauser
• 26 Aug 2021
Beat C. Bornhauser, PhD, of the University Children’s Hospital Zurich, Zurich, Switzerland, outlines chemoresistance and the importance of drug profiling in the treatment of acute lymphoblastic leukemia (ALL). Dr Bornhauser discusses the use of functional assays combined with imaging analysis algorithms to specifically evaluate the survival of leukemia cells in response to different drugs and doses. The combination of molecular and functional profiling in the clinical setting may enable the personalization of treatment and therefore improve patient outcomes. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
